VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum

被引：167

作者：

DePolo, NJ ^{[1
]}

Reed, JD ^{[1
]}

Sheridan, PL ^{[1
]}

Townsend, K ^{[1
]}

Sauter, SL ^{[1
]}

Jolly, DJ ^{[1
]}

Dubensky, TW ^{[1
]}

机构：

[1] Chiron Corp, Emeryville, CA 94608 USA

来源：

MOLECULAR THERAPY | 2000年 / 2卷 / 03期

关键词：

lentivirus vector; retroviral vector; complement; resistance; human sera inactivation; VSV G pseudotyping;

D O I：

10.1006/mthe.2000.0116

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Lentiviral vectors transduce dividing and postmitotic cells and thus are being developed toward therapies for many diseases affecting diverse tissues. One essential requirement for efficacy will be that vector particles are resistant to inactivation by human serum complement. Most animal studies with lentiviral vectors have utilized VSV-G pseudotyped envelopes. Here we demonstrate that VSV-G pseudotyped HIV and FIV vectors produced in human cells are inactivated by human serum complement, suggesting that alternative envelopes may be required for therapeutic efficacy for many clinical applications of lentiviral vectors.

引用

收藏

页码：218 / 222

页数：5

相关论文

共 37 条

[11] USE OF A NOVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPORTER VIRUS EXPRESSING HUMAN PLACENTAL ALKALINE-PHOSPHATASE TO DETECT AN ALTERNATIVE VIRAL RECEPTOR [J].

HE, JL ;

LANDAU, NR .

JOURNAL OF VIROLOGY, 1995, 69 (07) :4587-4592

[12] Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors [J].

Johnston, JC ;

Gasmi, M ;

Lim, LE ;

Elder, JH ;

Yee, JK ;

Jolly, DJ ;

Campbell, KP ;

Davidson, BL ;

Sauter, SL .

JOURNAL OF VIROLOGY, 1999, 73 (06) :4991-5000

[13] Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors [J].

Kafri, T ;

Blomer, U ;

Peterson, DA ;

Gage, FH ;

Verma, IM .

NATURE GENETICS, 1997, 17 (03) :314-317

[14]

Klimatcheva Ekaterina, 1999, Frontiers in Bioscience, V4, pD481, DOI 10.2741/Klimatcheva

[15] Human serum-resistant retroviral vector particles from galactosyl (α1-3) galactosyl containing nonprimate cell lines [J].

Mason, JM ;

Guzowski, DE ;

Goodwin, LO ;

Porti, D ;

Cronin, KC ;

Teichberg, S ;

Pergolizzi, RG .

GENE THERAPY, 1999, 6 (08) :1397-1405

[16] COMPLEMENT CONTROL PROTEINS, CD46, CD55, AND CD59, AS COMMON SURFACE CONSTITUENTS OF HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUSES AND POSSIBLE TARGETS FOR VACCINE PROTECTION [J].

MONTEFIORI, DC ;

CORNELL, RJ ;

ZHOU, JY ;

ZHOU, JT ;

HIRSCH, VM ;

JOHNSON, PR .

VIROLOGY, 1994, 205 (01) :82-92

[17] MEMBRANE-PROTEINS THAT PROTECT AGAINST COMPLEMENT LYSIS [J].

MORGAN, BP ;

MERI, S .

SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1994, 15 (04) :369-396

[18] Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector [J].

Naldini, L ;

Blomer, U ;

Gage, FH ;

Trono, D ;

Verma, IM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11382-11388

[19] In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [J].

Naldini, L ;

Blomer, U ;

Gallay, P ;

Ory, D ;

Mulligan, R ;

Gage, FH ;

Verma, IM ;

Trono, D .

SCIENCE, 1996, 272 (5259) :263-267

[20] Control of early viral and bacterial distribution and disease by natural antibodies [J].

Ochsenbein, AF ;

Fehr, T ;

Lutz, C ;

Suter, M ;

Brombacher, F ;

Hengartner, H ;

Zinkernagel, RM .

SCIENCE, 1999, 286 (5447) :2156-2159

← 1 2 3 4 →